Best Life Sciences Companies in Alpharetta, United States
The 44 best Life Sciences companies in Alpharetta, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Avanos.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Alpharetta
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Avanos Manufacturer of medical devices for pain management and enteral feeding | $250M | 91 mo ago | 5,003 | 2014 | Joe Woody CEO | WordPressMySQLPHP+25 | — | — |
| 2 | EndoChoice Range of devices, systems and services for GI specialists | $116M | 133 mo ago | 414 | 2008 | Will Parks Co-Founder & VP Business Development | — | 513 patents Patents concentrated in health & consumer products | — |
| 3 | QSpex Polarized, anti-reflective and photochromic eye-glass lenses | $107M | 113 mo ago | 33 | 2007 | — | — | 42 patents Advanced ophthalmic lens manufacturing: anti‑reflective, photochromic, and polarized lens technologies. | — |
| 4 | Alimera Sciences Developer of therapeutic solutions to treat diabetic macular edema (DME) | $67M | 38 mo ago | 79 | 2003 | Rick Eiswirth CEO | WordPressMySQLPHP+20 | — | — |
| 5 | Clearside Biomedical Developer of drug therapies to treat chronic, blinding diseases of the eye | $50M | 80 mo ago | 30 30 → 25 (-17%) | 2011 | George Lasezkay President and Chief Executive Officer | WordPressDrupalMySQL+26 | 223 patents Ocular drug delivery systems and formulations for intravitreal injection therapies. | — |
| 6 | Dune Medical Developer of intraoperative cancer detection devices | $46M | 109 mo ago | 20 | 2002 | Lori Chmura CEO | — | — | — |
| 7 | Inhibitex Polymerase inhibitor for the treatment of Hep C. | $35M | 202 mo ago | 34 | 1994 | — | — | 89 patents Antiviral nucleoside phosphoramidate/ phosphorodiamidate prodrugs and related synthesis | — |
| 8 | Carticept Medical Platform technology for injection procedure | $30M | 175 mo ago | 7 | 2005 | Tim Patrick President and CEO | — | — | — |
| 9 | Cartiva Synthetic cartilage implants for osteoarthritis patients | $23M | 115 mo ago | 36 | 2011 | — | — | 118 patents Foot and hand orthopedic implants and specialized surgical instrumentation. | — |
| 10 | Atherogenics Health information website providing news and articles on well-being | $21M | 259 mo ago | — | 1994 | Russell Medford CEO | — | 117 patents Patents concentrated in health & consumer products | — |
| 11 | Modify Health Provider of personalized diet focused meal services | $15M | 21 mo ago | 21 | 2007 | George Pratt Founder & CEO | Shogun Page BuilderCart FunctionalityShopify+39 | — | 2 partnerships |
| 12 | GQ Life Sciences Online search tools for life science research | $11M | 200 mo ago | 16 16 → 12 (-25%) | 2001 | — | — | 8,014 patents Integrated biomedical wearables, advanced drug delivery systems, and high-throughput biotech manufacturing | — |
| 13 | Annoviant Developer of a device for the treatment of congenital heart disease | $10M | 18 mo ago | — | 2018 | Naren Vyavahare Co-Founder | — | 3 patents Automated tissue processing and biomanufacturing platforms for cell and tissue engineering | — |
| 14 | Clinithink AI solutions unlocking healthcare insights from unstructured data, empowering better decisions | $7M | 28 mo ago | 43 | 2009 | — | — | — | — |
| 15 | Virios Therapeutics Provider of therapeutic solution for the treatment of diseases associated with the abnormal immune response | $6M | 72 mo ago | 5 | 2012 | — | WixSentryBootstrap+12 | — | — |
| 16 | Bruder Healthcare Products for dry eye and pain management | $5M | 206 mo ago | 20 | 1986 | — | WordPressMySQLPHP+33 | 45 patents Ophthalmic therapeutic compress devices and topical demodex control formulations | — |
| 17 | VTI Innovative eye care redefining vision with advanced contact lens technology | $5M | 79 mo ago | 37 | 2008 | Juan Carlos Aragón Chief Executive Officer & Executive Board Member | WordPressMySQLPHP+38 | 16 patents Precision slurry and manure delivery systems for agricultural machinery | — |
| 18 | Optomed Provider of handheld fundus cameras and software solutions for eye screening | $5M | 84 mo ago | 114 | 2004 | Seppo Kopsala Founder & CEO | WordPress Block EditorCart FunctionalityWooCommerce+54 | — | — |
| 19 | SanuWave Developer of Noninvasive devices, and biologics for wound healing | $1M | 26 mo ago | 38 38 → 80 (+111%) | 2005 | — | BootstrapPostHogGoogle Analytics+17 | 191 patents Catheter-based focused acoustic shock wave therapy for vascular and tissue medical treatments | — |
Top 12 Life Sciences companies in Alpharetta
#1
Seed · Alpharetta, Georgia · founded 2018$9.8Mraised▾
Developer of a device for the treatment of congenital heart disease. The device TxGuard is used for cardiovascular patches, valve conduit for CHD, and TAVR applications. It uses materials that are stable against enzymes and can regenerate when implanted.
- Feb 2025Grant (prize money)$4M
- Oct 2021Grant (prize money)$1.9M
- Nov 2020Seed$600K
- Sep 2020Grant (prize money)$327.8K
#2
Series C · Alpharetta, Georgia · founded 2007 · 21 employees$15.2Mraised▾
Provider of personalized diet-focused meal services. It provides a personalized diet plan with a scheduled pattern & delivers it to the consumer for fitness. Claims that ingredients are organic, nutrient-dense & sourced from locally-grown and the products are non-GMO, gluten-free, Low-FODMAP, dairy-free & soy-free. It also provides personalized meal plans to patients suffering from conditions such as Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD), Celiac Disease & others.,
- Nov 2024Series C$13.7M
- Jan 2023Series B$10M
- Aug 2022Series A$700K
- Aug 2020Series A$2.3M
#3
Acquired · Alpharetta, Georgia · founded 2003 · 79 employees$66.8Mraised▾
Alimera Sciences is a developer of therapeutic solutions to treat diabetic macular edema (DME). It specializes in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. It helps to treat early- and late-stage diseases such as diabetic macular edema (DME), wet and dry age-related macular degeneration (AMD) and retinal vein occlusion (RVO). The primary focus is on ILUVIEN (fluocinolone acetonide intravitreal implant), which is an intravitreal implant of fluocinolone acetonide for the treatment of DME.
- May 2023Post IPO$81M
- Oct 2019Post IPO$20M
- Jan 2018Conventional Debt$40M
- Feb 2014Post IPO$37.5M
#4
Series A · Alpharetta, Georgia · founded 2009 · 43 employees$7.2Mraised▾
AI solutions unlocking healthcare insights from unstructured data, empowering better decisions. The company provides AI-powered solutions for the life sciences and healthcare industries. Its core technology, CLiX, transforms unstructured clinical narrative into actionable insight by understanding the nuances of healthcare language. This enables organizations to rapidly identify patient cohorts, enhance clinical productivity, improve population health outcomes, and optimize revenue cycles. The company's solutions leverage real-world data to drive better decisions, faster action, and more meaningful results across the healthcare ecosystem. It offers AI for Life Sciences, AI for Population Health, and AI for Revenue Cycle solutions. The company's technology helps healthcare decision-makers improve patient outcomes, tackle inequalities, and enhance clinical productivity. It is a B2B, SaaS, and software company that uses Artificial Intelligence to provide solutions for healthcare.
- Apr 2024Series A—
- Jan 2019Series A—
- Jul 2012Series A$7.2M
#5
Public · Alpharetta, Georgia · founded 2005 · 38 employees$1.4Mraised▾
Developer of Noninvasive devices, and biologics for wound healing. The products include the dermaPACE System an acoustic wave therapy for an advanced wound care, UltraMIST System an ultrasound therapy, orthoPACE system which utilizes PACE technology for the treatment of chronic pain caused by musculoskeletal disorders and inflammatory conditions. The biologics include Biovance and Interfyl for the treatment of damaged tissues.
- Jun 2024Post IPO$1.8M
- Jan 2024Post IPO$4.6M
- Dec 2023Post IPO$1.9M
- Aug 2023Post IPO$3M
#6
Acquired · Alpharetta, Georgia · founded 2014 · 5003 employees$250Mraised▾
Manufacturer of medical devices for pain management and enteral feeding. Products include pain pumps, radiofrequency ablation systems, and enteral feeding tubes and accessories. These devices serve various medical specialties, including surgical pain, interventional pain, and neonatal care. The company offers solutions for hospitals, clinics, and home healthcare settings. Its product portfolio addresses both acute and chronic pain management needs, as well as nutritional support for patients requiring enteral feeding.
- Jan 2019Conventional Debt$250M
#7
Deadpooled · Alpharetta, Georgia · founded 2007 · 33 employees$107.2Mraised▾
QSpex Technologies, an optical service center, offers finished eyewear in the United States. It offers high impact, single vision, progressive, anti reflective, photochromic, and polar lenses. The lens treatments are pre-applied to the inside surface of each mold and transfer to become part of the lens during the polymerization process. According to the company, the fabrication and delivery of product is done within a day.
- Mar 2017Series F$3.8M
- Dec 2016Series F$1M
- Jul 2015Series F$34.5M
- Jan 2014Series E$15M
#8
Acqui-Hired · Alpharetta, Georgia · founded 2008 · 414 employees$116Mraised▾
EndoChoice, a platform GI company, provides devices, diagnostics, infection control and imaging for specialists treating gastrointestinal diseases. Went public in June 2015.
- Jun 2015Conventional Debt$58M
- Mar 2015Series E$57M
- Jan 2013Series D$43M
- Jan 2011Series C$4.5M
#9
Public · Alpharetta, Georgia · founded 2011 · 30 employees$50.3Mraised▾
Developer of drug therapies to treat chronic, blinding diseases of the eye. The company develops an ocular microinjection platform that targets the individual compartments of the eye. It provides a non-surgical application for dosing drugs to distinct eye tissues, such as the retina, trabecular meshwork, and corneal stroma. The product pipeline includes CLS-1001 for the treatment of macular edema associated with non-infectious uveitis.
- Dec 2019Post IPO$3.3M
- Dec 2015Series C$20M
- Sep 2014Series B$16.2M
- May 2014Series A$3M
#10
Acqui-Hired · Alpharetta, Georgia · founded 2002 · 20 employees$46.5Mraised▾
Dune Medical is a developer of intraoperative cancer detection devices. It uses spin-off from Misgav Technology Incubator is engaged in the development of intraoperative cancer detection devices. The MarginProbe system delivers real-time cancer detection in the OR for immediate assessment of cancer on the margin of excised tissue. MarginProbe has received FDA clearance.
- Jul 2017Series C$12.3M
- Jan 2017Grant (prize money)$3.2M
- Aug 2016Grant (prize money)$3M
- May 2014Series C$14M
#11
Acquired · Alpharetta, Georgia · founded 1994 · 34 employees$35Mraised▾
Inhibitex was focused on developing treatments for bacterial and viral infections. Its lead drug INX-189 (BMS-986094) is a nucleotide NS5B polymerase inhibitor for the treatment of Hep C. As of Jan 2012, BMS acquired Inhibitex for $2.5B. In Aug 2012, BMS halted the development of BMS-986094 due to patient death.
- Oct 2009Post IPO$23M
- Sep 2005Post IPO$41.2M
- Nov 2004Post IPO$49.7M
- Jan 2004Series E$20M
#12
Acquired · Alpharetta, Georgia · founded 2011 · 36 employees$22.8Mraised▾
Cartiva, spun out from Carticept Medical, is focused on developing therapies for osteoarthritis patients, characterized by the breakdown of the cartilage in the joint. Its products include Cartiva Synthetic Cartilage Implant for Pain associated with the thumb using a Polyvinyl Alchol biomaterial, and ProxiFuse Hammertoe Compression System for fusion of the lesser toes for hammertoe, claw toe and mallet toe deformities. In Jan 2015, the company received FDA 510(k) clearance for its ProxiFuse Hammertoe Compression System. In April 2016, the company announced positive review of Cartiva Synthetic Cartilage Implant from FDA Advisory committee.
- Jan 2017Venture Debt—
- Nov 2016Series E$8.5M
- Apr 2015Series D$8.5M
- Dec 2014Series C$1.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.